pain management in the hospitalized patient n.
Skip this Video
Download Presentation
Pain Management in the hospitalized patient

Loading in 2 Seconds...

play fullscreen
1 / 36

Pain Management in the hospitalized patient - PowerPoint PPT Presentation

  • Uploaded on

Joshua Vanderloo PharmD, RPh Clinical Pharmacist, University of Wisconsin Hospital and Clinics. Pain Management in the hospitalized patient. Disclosures. I have no actual or potential conflict of interest in relation to this presentation. . Objectives.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Pain Management in the hospitalized patient' - xiu

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
pain management in the hospitalized patient

Joshua Vanderloo PharmD, RPh

Clinical Pharmacist, University of Wisconsin Hospital and Clinics

Pain Management in the hospitalized patient

  • I have no actual or potential conflict of interest in relation to this presentation.
  • Identify importance of high quality pain management
  • Describe basic approaches and techniques for improving pain management in the hospitalized patient
  • Describe the role of non-opioid and opioid therapies in the management of pain in the hospitalized patient consistent with the WHO Pain Ladder.

Or: Framing the Discussion

why is high quality pain management important
Why is high quality pain management important?
  • High cost of unmanaged pain
    • Time
    • Costs
      • $60 billion lost productivity1 and reduced patient QOL2
    • Increased length of stay3
  • HCAHPS* scores related to pain
  • Managing primary diagnosis as well as pain

*HCAHPS: Hospital Consumer Assessment of Healthcare Providers and Systems

1National Institute of Neurological Disorders and Stroke. Peptides implicated in body’s response to pain.

2Postoperative pain management: a practical review, part 2. Am J Health-Syst Pharm. 2005; 62:2019-2025.

3Economic benefits of an acute interventional postoperative pain service. Anesth analg. 2007;104:S-75.

neuroplasticity in pain processing
Neuroplasticity in Pain Processing

Neuropathic pain

Acute pain  chronic pain syndromes

Cervero F. Pain. 1996


Descending Modulation

Central Sensitization

Peripheral Sensitization

Gottschalk A, Smith DS. Am Fam Physician. 2001

inhibiting pain
Inhibiting Pain
  • Inhibitory neurotransmitters  Decrease pain transmission
    • Opioids
    • Norepinephrine
    • Serotonin
    • GABA
  • Excitatory neurotransmitters  Increase pain transmission
    • Glutamate
    • NMDA
pain assessment
Pain Assessment


  • Quality
  • Region/Radiation
  • Severity
  • Timing
    • Onset/Duration
  • Palliative factors
  • Previous therapies
    • Successful and nonsuccessful
approaching pain treatment
Approaching Pain Treatment

Non-pharmacologic approaches


  • Ice
  • Heat
  • Repositioning
  • Distraction
  • Music
  • PT
  • OT
  • Continue home regimens
  • Opioids and non-opioids
  • Neuropathic pain
    • Adjuvants
who pain relief ladder
WHO Pain Relief Ladder

1. Initial pain: Nonopioids

2. Addition:

mild opioid or strong opioid with titration if pain inadequately managed

treatments for fear/anxiety if needed

3. Schedule medications instead of PRN – “around the clock”

Right drug, right dose, right time  80-90% effective and cost effective

World Health Organization (2009). WHO’s Pain Relief Ladder.

modified who pain relief ladder
Modified WHO Pain Relief Ladder

PO preferred

Regular intervals

Analgesic chosen according to intensity



Vargas-Schaffer G. Can Fam Physician. 2010.

  • Mechanism:
    • COX enzyme inhibition in CNS
    • Analgesic & antipyretic
  • Indication:
    • Mild to moderate non-inflammatory pain
    • First line for osteoarthritis
    • First line for pain control in the elderly
  • PO, IV
acetaminophen hepatotoxicity
Acetaminophen & Hepatotoxicity
  • Risk factors
    • Alcohol
    • Liver disease
    • > 4g daily
  • Daily dose limit
  • Inhibition of COX enzymes Prostaglandin synthesis inhibition
    • Antipyretic
    • Anti-inflammatory
  • Uses
    • Acute and chronic pain
    • Somatic pain
    • Opioid sparing
nsaids examples
NSAIDs - Examples
  • IbuprofenPO, IV
  • Ketorolac PO, IV
  • Naproxen PO
  • Aspirin PO, PR
  • Diclofenac PO, topical
  • Indomethacin PO, PR
nsaid adverse effects
NSAID Adverse Effects
  • Gastric, renal, cardiovascular, hematologic
  • Related to:
    • Dose
    • Length of treatment
    • Elderly
  • Role of COX-2 selective NSAIDs?
    • GI vs. cardiovascular risks
      • Decreasing GI risk
        • PPIs
        • Ibuprofen and diclofenac

ACG Guidelines. Am J Gastroenterol. 2009;104:728-738.

NSAID prescribing precautions. Am Fam Physician. 2009;80:1371-1378.

delivery and formulations of opioids
Delivery and formulations of Opioids



  • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Intrathecal
  • Transdermal
  • Immediate release
  • Extended release
  • PCA
  • Pumps
  • Patches
more advanced techniques
More advanced techniques
  • PCA
    • Dosing
      • Patient-initiated boluses
      • Clinician-initiated boluses
      • Basal rates
    • Adjusting
      • Attempts vs. deliveries
      • Sedation, end-tidal CO2
  • Epidurals
  • Intrathecal opioid ± clonidine ± local anesthetic
opioid side effects
Opioid Side Effects


Nausea and vomiting

CNS effects


Respiratory Depression

Less frequent: Opioid-induced Hyperalgesia, urinary retention, delirium, myoclonus

opioid constipation
Opioid Constipation
  • All segments of GI
    • Colon most pronounced
  • Increased transit time
    • Non-propulsive, spastic contractions
    • Electrolyte absorption?
  • Differing degrees among agents
    • PO formulations
  • Assume it will develop and will not tolerate
exacerbating opioid constipation
Exacerbating Opioid Constipation
  • Advanced age
  • Immobility
  • Other concurrent constipating medications
  • Intraabdominal pathologies
  • Neuropathy
  • Hypercalciemia
preventing opioid constipation
Preventing Opioid Constipation
  • Regular assessments of stooling
  • Dietary changes
  • Add preventative agents
    • Stool softener (e.g. docusate) and peristaltic stimulant/“contact cathartic”(e.g. sennosides)
    • Or osmotic laxative (e.g. lactulose or polyethylene glycol)
    • Especially for patients with consistent opioid use
  • Prophylactic management is ideal
treating opioid constipation
Treating Opioid Constipation
  • No BM in 48 hours
    • Addition of agents
      • Lactulose, sennosides, MoM
  • No BM in 72 hours
    • Fecal impaction assessment
      • If impacted:
        • Mineral oil enema ± irritant enema ± manual disimpaction
      • Following disimpaction:
        • Prevent constipation recurrence
  • Methylnaltrexone? Oral naltrexone?
opioid induced hyperalgesia oih
Opioid-induced Hyperalgesia (OIH)
  • Paradoxical response
    • Increased opioid exposure  pain sensitization
      • i.e. Loss of opioid efficacy
  • Suspect if
    • Opioid efficacy decreases with dose escalation
      • Especially if pain worsens or becomes more generalized
oih management
OIH Management
    • Detoxification
  • Dose reduction
  • Opioid rotation
  • Addition of NMDA-R antagonist
adjustments for organ dysfunction
Adjustments for Organ Dysfunction

Renal Insufficiency

Hepatic Insufficiency

pain management pearls
Pain Management Pearls
  • Multimodal approach
  • Prefer PO
    • Avoid IM
  • Schedule meds for persistent pain
  • Anticipate side effects and manage proactively
  • Avoid multiple opioids simultaneously
  • No maximum dose or analgesic ceiling
  • Continue to reassess pain and side effects
  • Cervero F, Laird JM. Mechanisms of touch-evoked pain (allodynia): a new model. Pain. 1996;68(1):13-23.
  • Gottschalk A, Smith DS. New concepts in acute pain therapy: preemptive analgesia. Am Fam Physician. 2001;63:1979-84.
  • Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56:514-517.
  • Holmquist GL, Leon-Casasola OA, McPherson ML, Herndon CM. Patient-centered approach to pain management. ASHP Midyear Meeting. New Orleans Convention Center. New Orleans, LA. 5 Decemeber 2011. Educational programming.
  • Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9:1-39.
  • Pain: Current understanding of assessment, management, and treatments. National Pharmaceutical Council website. Accessed May 27, 2012.
  • Rhodes L, Groninger H, Malchow, R. Key concepts in pain management for the federal healthcare professional. MedIQ website. Accessed May 27, 2012.
  • Fine PG, Bekanich SJ. Improving acute pain management in hospitalized patients with chronic pain disorders. MedIQ website. Accessed May 27, 2012.
  • Johnson SJ. Opioid safety in patients with renal or hepatic dysfunction. Pain Treatment Topics website. Accessed May 29, 2012.
pain management in the hospitalized patient1

Joshua Vanderloo PharmD, RPh

Clinical Pharmacist, University of Wisconsin Hospital and Clinics

Pain Management in the hospitalized patient